Cardiomyocytes (CMs) derived from human pluripotent stem cells (hPSCs) are considered a most promising option for cell-based cardiac repair. Hence, various protocols have been developed for differentiating hPSCs into CMs. Despite remarkable improvement in the generation of hPSC-CMs, without purification, these protocols can only generate mixed cell populations including undifferentiated hPSCs or non-CMs, which may elicit adverse outcomes. Therefore, one of the major challenges for clinical use of hPSC-CMs is the development of efficient isolation techniques that allow enrichment of hPSC-CMs. In this review, we will discuss diverse strategies that have been developed to enrich hPSC-CMs. We will describe major characteristics of individual hPSC-CM purification methods including their scientific principles, advantages, limitations, and needed improvements. Development of a comprehensive system which can enrich hPSC-CMs will be ultimately useful for cell therapy for diseased hearts, human cardiac disease modeling, cardiac toxicity screening, and cardiac tissue engineering.

中文翻译：

---

纯化人类多能干细胞来源的心肌细胞的当前策略和挑战

源自人多能干细胞（hPSC）的心肌细胞（CM）被认为是基于细胞的心脏修复的最有希望的选择。因此，已经开发了用于将hPSC区分为CM的各种协议。尽管在不纯化的情况下，hPSC-CM的产生有了显着改善，但这些方案只能产生混合细胞群，包括未分化的hPSC或非CM，这可能会引起不良后果。因此，hPSC-CMs临床使用的主要挑战之一是开发有效的分离技术，以使hPSC-CMs富集。在这篇综述中，我们将讨论为丰富hPSC-CM而开发的各种策略。我们将描述每种hPSC-CM纯化方法的主要特征，包括其科学原理，优势，局限性，并需要改进。开发能够丰富hPSC-CMs的综合系统，最终将可用于患病心脏的细胞治疗，人类心脏疾病模型，心脏毒性筛查和心脏组织工程。